106 related articles for article (PubMed ID: 7720180)
1. Long-term platinum excretion in patients treated with cisplatin.
Schierl R; Rohrer B; Hohnloser J
Cancer Chemother Pharmacol; 1995; 36(1):75-8. PubMed ID: 7720180
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin based chemotherapy in testicular cancer patients: long term platinum excretion and clinical effects.
Hohnloser JH; Schierl R; Hasford B; Emmerich B
Eur J Med Res; 1996 Sep; 1(11):509-14. PubMed ID: 9438151
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of platinum in chemotherapy-treated long-term survivors of testicular cancer.
Gerl A; Schierl R
Acta Oncol; 2000; 39(4):519-22. PubMed ID: 11041115
[TBL] [Abstract][Full Text] [Related]
4. [Platinum concentrations in human tissue after administration of cisplatin].
Tochigi T; Ono K; Yoshikawa K; Hoshi S; Orikasa S; Imai Y
Gan To Kagaku Ryoho; 1988 Feb; 15(2):269-75. PubMed ID: 3341789
[TBL] [Abstract][Full Text] [Related]
5. Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study.
Hjelle LV; Gundersen PO; Oldenburg J; Brydøy M; Tandstad T; Wilsgaard T; Fosså SD; Bremnes RM; Haugnes HS
Anticancer Res; 2015 Mar; 35(3):1619-25. PubMed ID: 25750319
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients.
Gouyette A; Apchin A; Foka M; Richard JM
Eur J Cancer Clin Oncol; 1986 Mar; 22(3):257-63. PubMed ID: 3709595
[TBL] [Abstract][Full Text] [Related]
7. Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors.
Boer H; Proost JH; Nuver J; Bunskoek S; Gietema JQ; Geubels BM; Altena R; Zwart N; Oosting SF; Vonk JM; Lefrandt JD; Uges DR; Meijer C; de Vries EG; Gietema JA
Ann Oncol; 2015 Nov; 26(11):2305-10. PubMed ID: 26347114
[TBL] [Abstract][Full Text] [Related]
8. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity.
Kern W; Braess J; Kotschofsky M; Samel S; Becker H; Hiddemann W; Schleyer E
Anticancer Res; 2002; 22(5):3099-102. PubMed ID: 12530050
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin pharmacokinetics using a five-day schedule during repeated courses of chemotherapy in germ cell tumors.
Bonetti A; Franceschi T; Apostoli P; Messori A; Sperotto L; Cetto GL; Molino A; Leone R
Ther Drug Monit; 1995 Feb; 17(1):25-32. PubMed ID: 7725373
[TBL] [Abstract][Full Text] [Related]
10. Adsorptive voltametry to determine platinum levels in plasma from testicular cancer patients treated with cisplatin.
Gelevert T; Messerschmidt J; Meinardi MT; Alt F; Gietema JA; Franke JP; Sleijfer DT; Uges DR
Ther Drug Monit; 2001 Apr; 23(2):169-73. PubMed ID: 11294519
[TBL] [Abstract][Full Text] [Related]
11. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection.
Kern W; Braess J; Kaufmann CC; Wilde S; Schleyer E; Hiddemann W
Anticancer Res; 2000; 20(5C):3679-88. PubMed ID: 11268439
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of free and total platinum species after short-term infusion of cisplatin.
Vermorken JB; van der Vijgh WJ; Klein I; Hart AA; Gall HE; Pinedo HM
Cancer Treat Rep; 1984 Mar; 68(3):505-13. PubMed ID: 6538459
[TBL] [Abstract][Full Text] [Related]
13. The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy.
Tothill P; Klys HS; Matheson LM; McKay K; Smyth JF
Eur J Cancer; 1992; 28A(8-9):1358-61. PubMed ID: 1515251
[TBL] [Abstract][Full Text] [Related]
14. Effect of time of cisplatin administration on its toxicity and pharmacokinetics in dogs.
Hardie EM; Page RL; Williams PL; Fischer WD
Am J Vet Res; 1991 Nov; 52(11):1821-5. PubMed ID: 1686160
[TBL] [Abstract][Full Text] [Related]
15. [Relationship between plasma and urinary platinum pharmacokinetics with cisplatin nephrotoxicity in breast cancer patients].
Guo JH
Zhonghua Zhong Liu Za Zhi; 1992 Mar; 14(2):150-3. PubMed ID: 1618086
[TBL] [Abstract][Full Text] [Related]
16. Effect of methotrexate on the pharmacokinetics and renal excretion of cisplatin.
Preiss R; Brovtsyn VK; Perevodchikova NI; Bychkov MB; Hüller H; Belova LA; Michailov P
Eur J Clin Pharmacol; 1988; 34(2):139-44. PubMed ID: 3383986
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin administered as a continuous 5-day infusion: plasma platinum levels and urine platinum excretion.
Belliveau JF; Posner MR; Ferrari L; Crabtree GW; Cummings FJ; Wiemann MC; O'Leary GP; Griffin H; Phaneuf MA; O'Rourke A
Cancer Treat Rep; 1986 Oct; 70(10):1215-7. PubMed ID: 3756943
[TBL] [Abstract][Full Text] [Related]
18. Uptake and retention of platinum in patients undergoing cisplatin therapy.
Jonson R; Börjesson J; Mattsson S; Unsgaard B; Wallgren A
Acta Oncol; 1991; 30(3):315-9. PubMed ID: 2036240
[TBL] [Abstract][Full Text] [Related]
19. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer.
Gietema JA; Meinardi MT; Messerschmidt J; Gelevert T; Alt F; Uges DR; Sleijfer DT
Lancet; 2000 Mar; 355(9209):1075-6. PubMed ID: 10744098
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
